Today's challenges and tomorrow's opportunities: Ligands to peroxisome proliferator-activated receptors as therapies for type 2 diabetes and the metabolic syndrome

Drug Development Research

Volumn 67, Issue 7, 2006, Pages 574-578

  Miller, Anne Reifel ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Metabolic syndrome; Peroxisome proliferator activated receptors; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; CREATININE; GLUCOSE; IMIGLITAZAR; INSULIN; LIPID; LIVER ENZYME; MURAGLITAZAR; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE;

ANEMIA; BIOTECHNOLOGY; BLADDER TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; EDEMA; ENZYME BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; RARE DISEASE; RECEPTOR AFFINITY; STROKE; WEIGHT GAIN;

EID: 33845232611     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20125     Document Type: Conference Paper

References (32)

1. Bodkin NL, Pill J, Meyer K, Hansen BC. 2003. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Hormone Metab Res 35:617-624.
2. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. 2005. Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 27:1181-1195.
3. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjobolm K, Karlsson U, Lindstedt EL, Bamberg K. 2001. Structure of the PPARα and - γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706.
4. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A, Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA, Ryono DE, Selan F, Hariharan N, Cheng PT. 2005. Design and synthesis of N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] phenyl] methyl]glycine[Muraglitazar/BMS-298585], a novel peroxisome proliferator- activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248-2250.
5. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. 2004. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36:295-304.
6. Digman C, Klein AK, Pittas AG. 2005. Leukopenia and thrombocytopenia caused by thiazolidinediones. Ann Intern Med 143:465-466.
7. Dressel U, Allen TL, Pippal JB, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. 2003. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17:2477-2493.
8. Duval C, Fruchart JC, Staels B. 2004. PPARα, fibrates, lipid metabolism and inflammation. Arch Mal Coeur 97:665-672.
9. Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldorsdottir S, Gause-Nilsson I. 2005. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48:1716-1725.
10. Fonseca V. 2003. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115:42S-48S.
11. Gale EAM. 2001. Lessons from the glitazones: a story of drug development. The Lancet 357:1870-1875.
12. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman P. 2005. Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes. Diabetes 54:ABS 83-OR, p A21.
13. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. 2005. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866.
14. Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M. 2003. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 26:307-313.
15. Knouff C, Auwerx J. 2005. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Rev 25:899-918.
16. Kramer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook A. 2005. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor d. Diabetes 54:1157-1163.
17. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956.
18. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. 2000. Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473:333-336.
19. Ljung B, Bamberg K, Dahllof B, Kjellstadt A, Oakes ND, Ostling J, Svensson L, Camejo G. 2002. AZ 242, a novel PPAR α/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43:1855-1863.
20. Mudaliar S, Chang AR, Henry RR. 2003. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9:406-416.
21. Nestro RW, Bell D, Bonow RO, Forseca V, Grundy SM, Horton ES, Winter ML, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. 2004. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263.
22. Nissen SE, Wolski K, Topol EJ. 2005. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294:2581-2586.
23. Oakes ND, Thalen P, Hultstrand T, Jacinto S, Camejo G, Wallin B, Ljung B. 2005. Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 289:R938-R946.
24. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. 2001. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311.
25. Oron-Herman M, Sela BA, Rosenthal T. 2005. Risk reduction therapy of syndrome X: comparison of several treatments. AJH 18:372-378.
26. Page RLI, Gozansky WS, Ruscin JM. 2003. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 23:945-954.
27. Rangwala SM, Rhodes B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA. 2003. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev Cell 5:657-663.
28. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. 2003. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929.
29. The Pink Sheet Daily. 2006. Bristol Joins The Ranks: Firm Bags Pargluva Development. Prescription Pharmaceutical and Biotechnology. May 18th, 2006, Number 009, Rockville, MD: FDC Reports, Inc.
30. Wagner JA, Chun X, Rippley RK, et al. 2003. Single and multiple doses of MK-767 (KRP-297) reduce free fatty acids (FFA) and lipids in healthy subjects. Diabetes 52:ABS 588-P.
31. Wang Y-X, Lee C-H, Tiep S, Yu RT, Ham J, Kang H, Evans RM. 2003. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113:159-170.
32. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. 2005. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidine-dione-induced fluid retention. Proc Natl Acad Sci USA 102: 9406-9411.